Phase 2 N=209 A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
Nocturia · Prostatic Hyperplasia
Primary: Change in Nocturia Episodes — -1.2; -1.0 episodes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
Aplastic Anemia
Primary: Patients Treated With Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) Achieving at Least a Partial Remission (PR) at 6 Months — 9 participants
Phase 2 N=26 A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration
Hereditary Angioedema
Primary: Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the…
Phase 2 N=12 Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
Coronary Restenosis
Primary: Phase I: Number of Participants With Dose-limiting Toxicities — 0; 0; 0; 0 participants
Phase 2 N=48 Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 4.90 Months
Phase 2 N=49 Neoadjuvant GW572016 to Treat Breast Cancer
Breast Cancer
Primary: Clinical Response — 3; 30; 11; 3 participants
Phase 2 N=523 Long-term Safety in Atrial Fibrillation Patients
Persistent or Permanent Nonvalvular Atrial Fibrillation
Primary: Bleeding: Number of Patients With Any Bleeding Event, During Treatment Period — 55; 56 Participants
Phase 2 N=177 Staying Well: A Clinical Trial of Mindfulness-Based Stress Reduction and Education Groups for HIV
HIV
Primary: Change in CD4 T-cell Count — -57.1; -70.3 cells/µl
Phase 2 N=123 Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
Heart Failure
Primary: Venous Angiotensin II Levels After 12 Weeks of Treatment — 0.91; 1.08; 0.66; 0.38 ratio
Phase 2 N=84 Novartis H1N1 Vaccine in Pregnant Women
Influenza
Primary: Number of Participants Reporting Maternal Complications of Pregnancy, Labor and Delivery — 0; 0; 0; 0 participants
Phase 2 N=25 Evaluation of TachoSil® Application on a Colorectal Anastomosis (TC-029-IM)
Colorectal Anastomosis
Primary: The Primary Endpoint is the Feasibility of the TachoSil® Application, Reported by the Combined Assessment of the Investigator and External Assessor — 1; 2; 1; 2…
Phase 2 N=60 To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
Nasopharyngeal Cancer
Primary: Comparing the Level of Urinary N-telopeptide (uNTx) in the Two Arms . — 75; 94; 29; 88 nM /mM — p=0.370
Phase 2 N=322 A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
Chronic Obstructive Pulmonary Disease
Primary: Exacerbation Rate — 1.20; 1.31 exacerbation per patient year — p=0.7282
Phase 2 N=159 Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
Macular Degeneration
Primary: Mean Change of CR/LT From Baseline at Week 12 — -153.5; -75.6; -169.2; -56.3 μm
Phase 2 N=60 Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
Head and Neck Cancer
Primary: Number of Patients Treated With ZD1839 With Chemotherapy and Hyperfractionated Radiation That Had a 1-year Survival — 52 participants